$0.46
−4.42%Oct 16, 2026, 13:00 UTC
REVELATION BIOSCIENCES, INC. announced a 1-for-7 reverse stock split of its common stock, effective October 20, 2026.
Source:Aug 19, 2026, 13:00 UTC
Revelation Biosciences selected Avance Clinical as the contract research organization for its Phase 2/3 TITAN study evaluating Gemini in patients with acute kidney injury.
Source:Aug 19, 2026, 00:00 UTC
Revelation Biosciences, Inc. granted restricted stock awards to CEO James Rolke and CFO Chester S. Zygmont III as part of their compensation.
Jul 10, 2026, 20:05 UTC
Revelation Biosciences adopted a stockholder rights plan and declared a dividend distribution of one right per share of common stock.
Source: